Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1063961 | 0.93 | HSP90AB1 (0.44) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL14028120 | 0.92 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1065138 | 0.90 | HSP90AB1 (0.43) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL4179772 | 0.89 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1064227 | 0.87 | HSP90AB1 (0.44) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL14046335 | 0.86 | MAPK13 (0.41) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1065530 | 0.86 | HSP90AB1 (0.43) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1065592 | 0.85 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1062125 | 0.85 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL4946909 | 0.85 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404603-A1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases | Glaxosmithkline LLC (US) | 2012-01-11 | — | — | EP | claimed |
| JP-4524072-B2 | — | — | 2010-08-11 | — | — | JP | claimed |
| US-20080268044-A1 | Novel Process and Formulations | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | claimed |
| EP-1954282-A2 | NOVEL PROCESS AND FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2008-08-13 | — | — | EP | claimed |
| US-7323472-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-29 | — | — | US | claimed |
| EP-1333833-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-10-24 | — | — | EP | claimed |
| WO-2007059500-A2 | NOVEL PROCESS AND FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2007-05-24 | — | — | WO | claimed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | claimed |
| EP-1333833-A2 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2003-08-13 | — | — | EP | claimed |
| WO-2002059083-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| EP-2404603-A1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases | Glaxosmithkline LLC (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2404603-A1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases | Glaxosmithkline LLC (US) | 2012-01-11 | — | — | EP | disclosed |
| US-8058282-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy | GLAXOSMITHKLINE LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058282-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy | GLAXOSMITHKLINE LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058282-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy | GLAXOSMITHKLINE LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-20050203109-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2005-09-15 | — | — | US | disclosed |
| US-20040209901-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | disclosed |
| EP-1333833-A2 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002059083-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268044-A1 | Novel Process and Formulations | UGT1A7, UGT2B7, CYP3A7 | MAPK14 2969/4885MAPK13 2574/4885MAPK12 2708/4885 |
| US-20040209901-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, MAPK7 | MAPK14 22/4885MAPK13 25/4885MAPK12 60/4885 |
| US-20050203109-A1 | Novel Compounds | MAPKAPK2, CREBBP, CDC42BPB | MAPK14 42/4885MAPK13 43/4885MAPK12 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.